Johnson & Johnson (JNJ) Income from Continuing Operations (2009 - 2026)
Johnson & Johnson (JNJ) posted Income from Continuing Operations of 5235000000.0 for Q1 2026, up 2.33% sequentially from 5116000000.0 in Q4 2025, and down 52.4% YoY from 10999000000.0 in Q1 2025.
Johnson & Johnson (JNJ) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Income from Continuing Operations data on file, last reported at 5235000000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 52.4% year-over-year to 5235000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21040000000.0 (down 3.53% YoY) and the FY2025 annual result came in at 26804000000.0, up 90.56% from the prior year.
- Income from Continuing Operations rose to 5235000000.0 in Q1 2026 per JNJ's latest filing, from 5116000000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 10999000000.0 in Q1 2025, with the low at 491000000.0 in Q2 2023.
- Average Income from Continuing Operations over 5 years is 4411647058.82, with a median of 4310000000.0 recorded in 2022.
- Year-over-year, Income from Continuing Operations sank 110.94% in 2023 and soared 762.93% in 2024.
- Johnson & Johnson's Income from Continuing Operations stood at 4310000000.0 in 2022, then dropped by 4.13% to 4132000000.0 in 2023, then declined by 16.97% to 3431000000.0 in 2024, then jumped by 49.11% to 5116000000.0 in 2025, then gained by 2.33% to 5235000000.0 in 2026.
- Business Quant data shows JNJ's Income from Continuing Operations at 5235000000.0 in Q1 2026, 5116000000.0 in Q4 2025, and 5152000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.40 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 5.24 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 697.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 833.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 319.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 5.24 Bn |
| Dec 28, 2025 | 5.12 Bn |
| Sep 28, 2025 | 5.15 Bn |
| Jun 29, 2025 | 5.54 Bn |
| Mar 30, 2025 | 11.00 Bn |
| Dec 29, 2024 | 3.43 Bn |
| Sep 29, 2024 | 2.69 Bn |
| Jun 30, 2024 | 4.69 Bn |
| Mar 31, 2024 | 3.26 Bn |
| Dec 31, 2023 | 4.13 Bn |
| Oct 1, 2023 | 4.31 Bn |
| Jul 2, 2023 | 5.38 Bn |
| Apr 2, 2023 | -491.00 Mn |
| Jan 1, 2023 | 2.65 Bn |
| Oct 2, 2022 | 4.31 Bn |
| Jul 3, 2022 | 4.12 Bn |
| Apr 3, 2022 | 4.49 Bn |
| Oct 3, 2021 | 3.67 Bn |
| Jul 4, 2021 | 6.28 Bn |
| Apr 4, 2021 | 6.20 Bn |